2026年全球乳癌液態生物檢體市場報告

乳癌液態生物檢體市場の規模は近年急速に拡大しております。2025年の8億9,000万米ドルから2026年には10億2,000万米ドルへと、CAGR 14.6％で成長が見込まれております。過去数年間の成長要素としては、乳癌罹患率の上昇、組織切片檢查の限界、腫瘍診断技術の進歩、検診意識の高まり、檢查室の拡充などが挙げられます。

乳癌液態生物檢體市場規模は今後数年間で急速な成長が見込まれます。2030年には14.3％のCAGRで17億5,000万米ドルに達する見通しです。予測期間における成長は、精密腫瘍学の導入、AIベースの変異解析、個別化治療計画、cfDNA検査の拡大、分散型がん診断などに起因すると考えられます。予測期間の主な動向としては、マルチバイオマーカー血液検査、非侵襲的がんモニタリング、治療反応追跡、早期再発検出、個別化腫瘍診断などが挙げられます。

The increasing number of 乳癌 cancer cases is expected to drive the growth of the 乳癌 液態生物檢體 market in the coming years. 乳癌 is a malignant tumor that develops in breast cells, particularly the milk-producing lobules and the milk ducts that transport milk to the nipple. The increasing incidence of 乳癌 cancer is thought to be due to factors such as genetic predisposition, hormonal imbalance, aging, lifestyle changes, obesity, alcohol consumption, cohol consumption, sphy. 乳癌 液態生物檢體 plays an important role in treatment by detecting circulating tumor DNA (ctDNA) or 循環性腫瘤細胞(CTCs) in the blood, enabling real-time disease monitoring. Thiseffps. genetic mutations for 標靶治療. 例如，根據美國癌症協會（一家致力於癌症研究、教育、宣傳和患者支持的美國非營利組織）預測，2024年新增乳癌病例數為313,510例，2025年將增至319,750例。因此，乳癌發生率的上升正在推動乳癌液態生物檢體市場的擴張。

乳癌液態生物檢體市場の主要企業は、特定の治療方法から最も恩恵を受ける可能性が高い患者を特定し、個別化治療を促進するためのコンパニオン診断薬などの革新的開発に注力しています。コンパニオン診断薬は、液態生物檢體技術を活用して、治療反応性を示す遺伝子変異、循環腫瘍DNA（ctDNA）、タンパク質発現などのバイオマーカーを検出します。例えば、2023年1月には、米国バイオテクノロジー企業であるガードアント,ヘルス社が、進行性または転移性乳癌患者でESR1変異を有する患者向けの治療薬であるメナリーニ,グループのオルセルデュ（エラセストラント）のコンパニオン診断として、同社のガードアント360 CDx液態生物檢體検査が米国食品藥物管理局（FDA）の核准を取得しました。この核准により、腫瘍専門医は本検査を用いた包括的ゲノムプロファイリングを実施し、標靶治療の恩恵を受け得る患者を特定することが可能となります。また、ガードアント,ヘルス社にとって乳癌領域初のFDA核准となり、精密腫瘍学分野における同社の存在感を強化するものです。

目錄

第1章執行摘要

第2章 市場特徵

• 市場定義和範圍
• 市場區隔
• 主要產品和服務概述
• 全球乳癌液態生物檢體市場：吸引力評分及分析
• 成長潛力分析、競爭評估、策略契合度評估、風險狀況評估

第3章 市場供應鏈分析

• 供應鏈與生態系概述
• 主要原料、資源和供應商清單
• 主要經銷商和通路合作夥伴名單
• 主要最終用戶列表

第4章 全球市場趨勢與策略

• 關鍵技術和未來趨勢
  • 生物技術、基因組學和精準醫學
  • 人工智慧（AI）和自主人工智慧
  • 數位化、雲端運算、巨量資料、網路安全
  • 工業4.0和智慧製造
  • 物聯網、智慧基礎設施和互聯生態系統
• 主要趨勢
  • 多生物標記血液檢測
  • 非侵入性癌症監測
  • 治療結果追蹤
  • 早期復發檢測
  • 個人化癌症診斷

第5章 終端用戶產業市場分析

• 醫院
• 診斷檢查室
• 醫師檢查室
• 研究所
• 病理檢查室

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及新冠疫情對市場的影響

第7章 全球策略分析架構、目前市場規模、市場對比及成長率分析

• 全球乳癌液態生物檢體市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
• 全球乳癌液態生物檢體市場規模、對比及成長率分析
• 全球乳癌液態生物檢體市場表現：規模與成長，2020-2025年
• 全球乳癌液態生物檢體市場預測：規模和成長，2025-2030年，2035年預測

第8章 全球潛在市場總量（TAM）

第9章 市場細分

• 依產品
• 耗材、套件
• 透過生物標記
• 細胞外囊泡（EVs）、遊離DNA（cfDNA）、循環腫瘤RNA（ctRNA）、循環性腫瘤細胞（CTCs）、遊離RNA（cfRNA）和其他生物標記
• 透過使用
• 早期発見または篩檢、診断、その他の用途
• 最終用戶
• 實驗室、醫院、醫生檢查室、參考檢查室、公共衛生實驗室、研究機構、小分子實驗室、病理檢查室
• 按類型細分：消耗品
• 試劑、聚合酵素鏈鎖反應(PCR) 檢測、定序板、檢體體採集管
• 按類型細分：套裝
• 以DNA為基礎的液態生物檢體盒、以RNA為基礎的液態生物檢體盒、多標記液態生物檢體盒

第10章 區域與國家分析

• 全球乳癌液態生物檢體市場：按地區、績效和預測分類，2020-2025年、2025-2030年預測、2035年預測
• 全球乳癌液態生物檢體市場：按國家/地區、績效和預測分類，2020-2025年、2025-2030年預測、2035年預測

第11章 亞太市場

第12章：中國市場

第13章 印度市場

第14章 日本市場

第15章：澳洲市場

第16章 印尼市場

第17章 韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章：西歐市場

第21章英國市場

第22章 德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章 東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章 南美洲市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

• 乳癌液態生物檢體市場：競爭格局及市場佔有率（2024年）
• 乳癌液態生物檢體市場：公司估值矩陣
• 乳癌液態生物檢體市場：企業プロファイル
  • Johnson & Johnson Private Limited
  • Roche Diagnostics
  • Merck KGaA
  • Thermo Fisher Scientific
  • Siemens Healthineers

第37章：其他領先和創新企業

• Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen NV, Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc.

第38章 全球市場競爭基準分析與儀錶板

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

• 2030年乳癌液態生物檢體市場：提供新機會的國家
• 2030年乳癌液態生物檢體市場：新興細分市場機會
• 2030年乳癌液態生物檢體市場：成長策略
  • 基於市場趨勢的策略
  • 競爭對手策略

第41章附錄

A breast cancer liquid biopsy is a minimally invasive test that detects and analyzes tumor-derived materials in a patient's blood or other bodily fluids, offering valuable insights into the presence, progression, and genetic profile of breast cancer without the need for a traditional tissue biopsy.

The primary products used in breast cancer liquid biopsy include consumables and kits. Consumables refer to disposable materials, reagents, and kits utilized in liquid biopsy tests to detect and analyze biomarkers associated with breast cancer. The key biomarkers include extracellular vesicles (EVs), cell-free DNA (cfDNA), circulating tumor RNA (ctRNA), circulating tumor cells (CTCs), cell-free RNA (cfRNA), and others. These biomarkers are applied in early detection or screening, diagnosis, and other purposes. The end users of breast cancer liquid biopsy encompass laboratories, hospitals, physician laboratories, reference laboratories, public health laboratories, research institutes, small molecular laboratories, and pathology laboratories.

Tariffs have created cost pressures in the breast cancer liquid biopsy market by impacting the supply of sequencing reagents, PCR consumables, and diagnostic kits. Consumables and kits segments are most affected, particularly in North America and Europe due to dependence on Asia-Pacific manufacturing hubs. While tariffs have increased testing costs, they have also encouraged local kit manufacturing, reagent optimization, and development of cost-efficient multi-marker solutions.

The breast cancer liquid biopsy market research report is one of a series of new reports from The Business Research Company that provides breast cancer liquid biopsy market statistics, including breast cancer liquid biopsy industry global market size, regional shares, competitors with a breast cancer liquid biopsy market share, detailed breast cancer liquid biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer liquid biopsy industry. This breast cancer liquid biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The breast cancer liquid biopsy market size has grown rapidly in recent years. It will grow from $0.89 billion in 2025 to $1.02 billion in 2026 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to rising breast cancer prevalence, limitations of tissue biopsy, oncology diagnostic advancements, increased screening awareness, laboratory testing expansion.

The breast cancer liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $1.75 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to precision oncology adoption, AI-based mutation analysis, personalized treatment planning, growth in cfDNA testing, decentralized cancer diagnostics. Major trends in the forecast period include multi-biomarker blood-based testing, non-invasive cancer monitoring, treatment response tracking, early recurrence detection, personalized oncology diagnostics.

The rising number of breast cancer cases is expected to drive the growth of the breast cancer liquid biopsy market in the coming years. Breast cancer is a malignancy that originates in the breast cells, typically in the milk-producing lobules or the ducts that transport milk to the nipple. The increasing prevalence of breast cancer is attributed to factors such as genetic predisposition, hormonal imbalances, an aging population, lifestyle changes, obesity, alcohol consumption, physical inactivity, radiation exposure, and environmental pollutants. Breast cancer liquid biopsy plays a crucial role in treatment by detecting circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood, enabling real-time disease monitoring. It helps assess treatment response, detect therapy resistance, and identify genetic mutations for targeted therapies. For example, according to the American Cancer Society, a US-based nonprofit organization dedicated to cancer research, education, advocacy, and patient support, new breast cancer cases are projected to increase from 313,510 in 2024 to 319,750 in 2025. As a result, the growing incidence of breast cancer is fueling the expansion of the breast cancer liquid biopsy market.

Leading companies in the breast cancer liquid biopsy market are focusing on innovative developments, such as companion diagnostics, to facilitate personalized treatment by identifying patients who are most likely to benefit from specific therapies. Companion diagnostics leverage liquid biopsy technology to detect biomarkers, including genetic mutations, circulating tumor DNA (ctDNA), and protein expressions that indicate treatment responsiveness. For instance, in January 2023, Guardant Health Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Menarini Group's ORSERDU (elacestrant), a therapy for advanced or metastatic breast cancer patients with ESR1 mutations. This approval allows oncologists to conduct comprehensive genomic profiling using the test, enabling them to identify patients who may benefit from targeted therapy. It also marks Guardant Health's first FDA approval for breast cancer, strengthening its presence in precision oncology.

In January 2024, Guardant Health Inc. partnered with Hikma Pharmaceuticals plc to enhance early cancer detection, monitor recurrence, and optimize treatment selection using Guardant Health's advanced liquid and tissue biopsy technologies. This collaboration strengthens Guardant Health's global presence and addresses the increasing cancer burden in the Middle East and North Africa. Hikma Pharmaceuticals plc is a UK-based pharmaceutical company specializing in innovative healthcare solutions.

Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

North America was the largest region in the breast cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the breast cancer liquid biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The breast cancer liquid biopsy market consists of revenues earned by entities by providing services such as early cancer detection, treatment monitoring, minimal residual disease (MRD) detection, recurrence prediction, and genetic mutation analysis for targeted therapy selection. The market value includes the value of related goods sold by the service provider or included within the service offering. The breast cancer liquid biopsy market also includes sales of circulating tumor DNA (ctDNA) assay kits, circulating tumor cell (CTC) detection systems, next-generation sequencing (NGS) panels, PCR-based liquid biopsy tests, blood collection tubes, and consumables and reagents used for non-invasive cancer diagnostics and monitoring. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Breast Cancer Liquid Biopsy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses breast cancer liquid biopsy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for breast cancer liquid biopsy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The breast cancer liquid biopsy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Consumables; Kits
• 2) By Biomarkers: Extracellular Vesicles (EVs); Cell-free DNA (cfDNA); Circulating Tumor RNA (ctRNA); Circulating Tumor Cells (CTCs); Cell-free RNA (cfRNA); Other Biomarkers
• 3) By Application: Early Detection Or Screening; Diagnosis; Other Applications
• 4) By End Users: Laboratories; Hospitals; Physician Laboratories; Reference Laboratories; Public Health Laboratories; Research Institutes; Small Molecular Laboratories; Pathology Laboratories
• Subsegments:
• 1) By Consumables: Reagents; Polymerase Chain Reaction (PCR) Assays; Sequencing Panels; Sample Collection Tubes
• 2) By Kits: DNA-based Liquid Biopsy Kits; RNA-based Liquid Biopsy Kits; Multi-marker Liquid Biopsy Kits
• Companies Mentioned: Johnson & Johnson Private Limited; Roche Diagnostics; Merck KGaA; Thermo Fisher Scientific; Siemens Healthineers; Agilent Technologies Inc.; Illumina Inc.; Sysmex Corporation; Qiagen N.V.; Myriad Genetics Inc.; NeoGenomics Laboratories; Guardant Health Inc.; Twist Bioscience; Foundation Medicine Inc.; Biodesix Inc.; Menarini Silicon Biosystems; Datar Cancer Genetics; Abcam plc; OncoDNA SA; Genomic Health Inc.; RainDance Technologies; Biocept Inc.; Fluxion Biosciences Inc.; Angle plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Breast Cancer Liquid Biopsy Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Breast Cancer Liquid Biopsy Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Breast Cancer Liquid Biopsy Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Breast Cancer Liquid Biopsy Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Multi-Biomarker Blood-Based Testing
  • 4.2.2 Non-Invasive Cancer Monitoring
  • 4.2.3 Treatment Response Tracking
  • 4.2.4 Early Recurrence Detection
  • 4.2.5 Personalized Oncology Diagnostics

5. Breast Cancer Liquid Biopsy Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Diagnostic Laboratories
• 5.3 Physician Laboratories
• 5.4 Research Institutes
• 5.5 Pathology Laboratories

6. Breast Cancer Liquid Biopsy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Breast Cancer Liquid Biopsy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Breast Cancer Liquid Biopsy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Breast Cancer Liquid Biopsy Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Breast Cancer Liquid Biopsy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Breast Cancer Liquid Biopsy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Breast Cancer Liquid Biopsy Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Breast Cancer Liquid Biopsy Market Segmentation

• 9.1. Global Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Consumables, Kits
• 9.2. Global Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers
• 9.3. Global Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Early Detection Or Screening, Diagnosis, Other Applications
• 9.4. Global Breast Cancer Liquid Biopsy Market, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories
• 9.5. Global Breast Cancer Liquid Biopsy Market, Sub-Segmentation Of Consumables, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes
• 9.6. Global Breast Cancer Liquid Biopsy Market, Sub-Segmentation Of Kits, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

10. Breast Cancer Liquid Biopsy Market Regional And Country Analysis

• 10.1. Global Breast Cancer Liquid Biopsy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Breast Cancer Liquid Biopsy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Breast Cancer Liquid Biopsy Market

• 11.1. Asia-Pacific Breast Cancer Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Breast Cancer Liquid Biopsy Market

• 12.1. China Breast Cancer Liquid Biopsy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Breast Cancer Liquid Biopsy Market

• 13.1. India Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Breast Cancer Liquid Biopsy Market

• 14.1. Japan Breast Cancer Liquid Biopsy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Breast Cancer Liquid Biopsy Market

• 15.1. Australia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Breast Cancer Liquid Biopsy Market

• 16.1. Indonesia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Breast Cancer Liquid Biopsy Market

• 17.1. South Korea Breast Cancer Liquid Biopsy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Breast Cancer Liquid Biopsy Market

• 18.1. Taiwan Breast Cancer Liquid Biopsy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Breast Cancer Liquid Biopsy Market

• 19.1. South East Asia Breast Cancer Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Breast Cancer Liquid Biopsy Market

• 20.1. Western Europe Breast Cancer Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Breast Cancer Liquid Biopsy Market

• 21.1. UK Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Breast Cancer Liquid Biopsy Market

• 22.1. Germany Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Breast Cancer Liquid Biopsy Market

• 23.1. France Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Breast Cancer Liquid Biopsy Market

• 24.1. Italy Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Breast Cancer Liquid Biopsy Market

• 25.1. Spain Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Breast Cancer Liquid Biopsy Market

• 26.1. Eastern Europe Breast Cancer Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Breast Cancer Liquid Biopsy Market

• 27.1. Russia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Breast Cancer Liquid Biopsy Market

• 28.1. North America Breast Cancer Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Breast Cancer Liquid Biopsy Market

• 29.1. USA Breast Cancer Liquid Biopsy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Breast Cancer Liquid Biopsy Market

• 30.1. Canada Breast Cancer Liquid Biopsy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Breast Cancer Liquid Biopsy Market

• 31.1. South America Breast Cancer Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Breast Cancer Liquid Biopsy Market

• 32.1. Brazil Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Breast Cancer Liquid Biopsy Market

• 33.1. Middle East Breast Cancer Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Breast Cancer Liquid Biopsy Market

• 34.1. Africa Breast Cancer Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Breast Cancer Liquid Biopsy Market, Segmentation By Product, Segmentation By Biomarkers, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Breast Cancer Liquid Biopsy Market Regulatory and Investment Landscape

36. Breast Cancer Liquid Biopsy Market Competitive Landscape And Company Profiles

• 36.1. Breast Cancer Liquid Biopsy Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Breast Cancer Liquid Biopsy Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Breast Cancer Liquid Biopsy Market Company Profiles
  • 36.3.1. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Roche Diagnostics Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis

37. Breast Cancer Liquid Biopsy Market Other Major And Innovative Companies

• Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc.

38. Global Breast Cancer Liquid Biopsy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Breast Cancer Liquid Biopsy Market

40. Breast Cancer Liquid Biopsy Market High Potential Countries, Segments and Strategies

• 40.1 Breast Cancer Liquid Biopsy Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Breast Cancer Liquid Biopsy Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Breast Cancer Liquid Biopsy Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer